Karim Benihoud

Dr. Karim Benihoud


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
CBChristian Bressy
Christian Bressy
DMDragomira Majhen
Dragomira Majhen
NRNajat Raddi
Najat Raddi
WJWael Jdey
Wael Jdey
GCGaétan Cornilleau
Gaétan Cornilleau
KBKarim Benihoud
Karim Benihoud
Combined therapy of colon carcinomas with an oncolytic adenovirus and valproic acid Combined therapy of colon carcinomas with an oncolytic adenovirus and valproic acid

5 February 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
AAAleksandra Anchim
Aleksandra Anchim
NRNajat Raddi
Najat Raddi
LZLena Zig
Lena Zig
PPPatrick Perrieau
Patrick Perrieau
RGRonan Le Goffic
Ronan Le Goffic
KBKarim Benihoud
Karim Benihoud
The use of serotype 5 adenovirus (Ad)-derived vectors in vaccination is confronted to preexisting anti-Ad immunity. Epitope display on Ad capsid is currently being investigated as an alternative approach of vaccination. The present study seeks to better understand virus- and host-related factors controlling the efficacy of this new vaccination approach. In contrast to an Ad vector expressing ovalbumin as a transgene, Ad displaying an ovalbumin-derived B-cell epitope inserted into the fiber protein was able to elicit antibody responses in both Ad-naive and Ad-immune mice. Moreover, introduction of a set of mutations abrogating Ad interaction with its receptors did not modify the virus capacity to elicit a humoral response against the inserted epitope while reducing its capacity to mount antibody responses against the transgene product. Taken as a whole these data indicate that the efficacy of Ad displaying epitopes requires neither Ad binding to its receptors nor the infection process. In addition, the use of genetically deficient mice demonstrated that both toll-like receptor (TLR)/MyD88 and RIG-I/mitochondrial antiviral-signaling (MAVS) innate immunity pathways were dispensable to mount anti-epitope antibody responses. However, they also revealed that TLR/MyD88 pathway but not RIG-I/MAVS pathway controls the nature of antibodies directed against the displayed epitope.

1 February 2022 in Life Sciences
Verified
Journal Article
Closed access
DNDavor Nestić
Davor Nestić
AHAmela Hozić
Amela Hozić
ZBZlatko Brkljača
Zlatko Brkljača
ABAna Butorac
Ana Butorac
KPKristijan Pažur
Kristijan Pažur
DMDragomira Majhen
Dragomira Majhen

4 January 2024 in npj Vaccines
Verified
Journal Article
Open access
PDF file
EVEmeline Vernhes
Emeline Vernhes
LCLinda Larbi Chérif
Linda Larbi Chérif
NDNicolas Ducrot
Nicolas Ducrot
CVClément Vanbergue
Clément Vanbergue
MOMalika Ouldali
Malika Ouldali
KBKarim Benihoud
Karim Benihoud
The promises of vaccines based on virus-like particles stimulate demand for universal non-infectious virus-like platforms that can be efficiently grafted with large antigens. Here, we harnessed the modularity and extreme affinity of the decoration protein pb10 for the capsid of bacteriophage T5. SPR experiments demonstrated that pb10 fused to mCherry or to the model antigen ovalbumin (Ova) retained picomolar affinity for DNA-free T5 capsid-like particles (T5-CLPs), while cryo-EM studies attested to the full occupancy of the 120 capsid binding sites. Mice immunization with CLP-bound pb10-Ova chimeras elicited strong long-lasting anti-Ova humoral responses involving a large panel of isotypes, as well as CD8+ T cell responses, without any extrinsic adjuvant. Therefore, T5-CLP constitutes a unique DNA-free bacteriophage capsid able to display a regular array of large antigens through highly efficient chemical-free anchoring. Its ability to elicit robust immune responses paves the way for further development of this novel vaccination platform.

6 April 2026 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
SLSalomé Laurans
Salomé Laurans
SHSoizic Huerre
Soizic Huerre
ODOlivier Dellis
Olivier Dellis
CFCéline Férard
Céline Férard
HJHadrien Jalaber
Hadrien Jalaber
SDSophie Dupré-Crochet
Sophie Dupré-Crochet
Adenoviruses are common pathogens that have been engineered and used for medical purposes. While their recognition by innate immune cells such as macrophages and dendritic cells is well characterized, interactions with neutrophils remain poorly understood. Using cytometry,confocal and electron microscopy, we showed that neutrophils bind to antibody-coated adenoviruses and engulf them in a phagosome. Single-cell transcriptomic approach reveals that adenovirus phagocytosis activates a specific transcriptional program in neutrophils. It also triggers calcium entry, reactive oxygen species production in the phagosome and CXCL8 release. Moreover, 4 hours after adenovirus incubation, 50% of neutrophils undergo calcium- and RIPK3-dependent cell death, accompanied by Neutrophil Extracellular Trap emission. This rapid cell death impaired complete viral degradation after 3 hours, allowing residual adenoviruses to retain genomic expression potential in target cells Thus, our data suggest that, during adenoviral infection, the neutrophil response may promote a pro-inflammatory environment that could damage host tissues.

17 December 2022 in OncoImmunology
Verified
Journal Article
Open access
BTBao-Tram Thi Tran
Bao-Tram Thi Tran
AGAurore Gelin
Aurore Gelin
SDSylvère Durand
Sylvère Durand
MTMatthieu Texier
Matthieu Texier
ADAmaury Daste
Amaury Daste
CECaroline Even
Caroline Even
Extra-cellular galectins 1, 3 and 9 (gal-1, −3 and −9) are known to act as soluble immunosuppressive agents in various malignancies. Previous publications have suggested that their expression is dependent on the metabolic status of producing cells and reciprocally that they can influence metabolic pathways in their target cells. Very little is known about the status of gal-1, −3 and −9 in patients bearing head and neck squamous cell carcinomas (HNSCC) and about their relationships with the systemic metabolic condition. This study was conducted in plasma samples from a prospective cohort of 83 HNSCC patients with advanced disease. These samples were used to explore the distribution of gal-1, −3 and −9 and simultaneously to profile a series of 87 metabolites assessed by mass spectrometry. We identified galectin and metabolic patterns within five disease categories defined according to the primary site and human papillomavirus (HPV) status (HPV-positive and -negative oropharyngeal carcinomas, carcinomas of the oral cavity, hypopharynx and larynx carcinomas). Remarkably, samples related to hypopharyngeal carcinomas displayed the highest average concentration of gal-9 (p = .017) and a trend toward higher concentrations of kynurenine, a potential factor of tumor growth and immune suppression. In contrast, there was a tendency toward higher concentrations of fatty acids in samples related to oral cavity. These observations emphasize the diversity of HPV-negative HNSCCs. Depending on their primary site, they evolve into distinct types of immune and metabolic landscapes that seem to be congruent with specific oncogenic mechanisms.